FMP
Marker Therapeutics, Inc.
MRKR
NASDAQ
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
1.1 USD
-0.1 (-9.09%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
21.35M
42.35M
11.78M
15.11M
19.19T
10.49T
16.7T
26.59T
42.33T
67.39T
4.57k
3.41k
130.85
456.38
291.19
100
100
100
100
1M
237
2.4M
1.03M
2.35T
4.06T
6.46T
10.28T
16.37T
26.06T
214.35
0.02
26.68
31.04
35.6
38.67
38.67
38.67
38.67
-1M
-
-
-988.13k
-
-2.72T
-4.34T
-6.91T
-10.99T
-17.5T
-214.23
-
-
-29.84
-
-25.97
-25.97
-25.97
-25.97
2.94M
5.14M
1.1M
961k
-
5.06T
8.06T
12.83T
20.42T
32.51T
628.77
414.27
12.23
29.02
-
48.25
48.25
48.25
48.25
-10.43M
-3.13M
-4.95M
-
-
-5.35T
-8.52T
-13.56T
-21.58T
-34.36T
-2.23k
-252.16
-54.92
-
-
-50.98
-50.98
-50.98
-50.98